Drug · DIN 02271397
FASTURTEC
No: cancelled before it was sold
Authorized, then cancelled before it was ever sold in Canada.
Status Cancelled Pre Market since January 16, 2023.
- Drug Identification Number (DIN)
- 02271397
- Company (DIN owner)
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Schedule
- Prescription; Schedule d
- Dosage form
- Powder For Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Rasburicase V03AF07
- Class
- Human
- Record last updated
- June 25, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| RASBURICASE | 7.5 MG | VIAL |
Notices of Compliance
Health Canada approvals that name this DIN.
- March 29, 2006: NOC 7845New Drug Submission (NDS) · Manufacturer name change
- September 15, 2005: NOC 7379Supplement to a New Drug Submission (SNDS) · New presentation
Other DINs named FASTURTEC
- DIN 02248416 · Marketed